Cosmo announces FDA grants orphan-drug designation of rifamycin for treatment of pouchitis
Cosmo Pharmaceuticals N.V. (“Cosmo”) announces that the FDA has granted the orphan-drug designation request of rifamycin for treatment of pouchitis.